Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Edwards, a leader in semiconductor supply, is investing in a new 200,000-square-foot manufacturing facility in Chandler, Arizona. This facility will utilize advanced technologies to support the growing semiconductor market, creating approximately 200 jobs locally. With construction underway, the site will begin operations in Q3, focusing on the remanufacturing and assembly of vacuum pump equipment essential for semiconductor fabrication. This investment underlines Edwards' commitment to sustainable practices and enhancing supply chain capacity in North America.
Agilent Technologies Inc. (NYSE: A) announced that CFO Bob McMahon will participate in Q&A sessions at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 11:10 a.m. EST, and the Barclays Global Health Care Conference on March 16, 2022, at 2:05 p.m. EDT. Both events will be webcast live, with access links available prior to the sessions on Agilent's Investor Relations website. Agilent is a leader in life sciences and diagnostic markets, generating $6.32 billion in revenue in fiscal 2021.
Agilent Technologies Inc. (NYSE: A) and the University of Vermont (UVM) have launched the Agilent Laboratory for Chemical Analysis (ALCA) in Santa Clara, California, and Burlington, Vermont. This facility aims to advance research in chemical composition and structure, benefiting students, academic staff, and regional businesses. The laboratory will provide state-of-the-art instrumentation and act as a technology resource for local start-ups. Agilent's commitment to science and local community support is emphasized by its investment in this innovative educational space.
Agilent Technologies Inc. (NYSE: A) and QIMR Berghofer Medical Research Institute have developed a novel COVID-19 saliva testing method using the Agilent Cary 630 FTIR Spectrometer. This proof-of-concept study analyzes the body's immune response rather than detecting the virus, making it potentially more effective against mutations. The research highlights the simplicity and rapidity of the method, which requires minimal equipment and provides results in seconds. Published in the journal Biomedicines, the study underscores the Cary 630's suitability for various settings, enhancing COVID-19 diagnostics.
Agilent Technologies reported a strong start to 2022, with revenue of $1.67 billion, marking an 8% growth year-over-year and 9% growth on a core basis. GAAP net income was $283 million with EPS of $0.93, consistent with the same period last year. The company raised its full-year revenue outlook to $6.67 billion to $6.73 billion, reflecting 5.6% to 6.5% growth. Non-GAAP EPS guidance was increased to $4.80 to $4.90. Agilent attributed its performance to a strong order book and confident management outlook.
Agilent Technologies Inc. (NYSE: A) has acquired advanced AI technology from Virtual Control. This technology, known as ACIES, will enhance Agilent's gas chromatography/mass spectrometry (GC/MS) platforms, improving efficiency and accuracy in lab workflows. The acquisition includes software and assets, with core ACIES team members joining Agilent. The integration is expected to benefit multiple sectors, including food testing and environmental applications, and aims to elevate lab productivity through innovative digital solutions.
Agilent Technologies, Inc. (NYSE: A) has declared a quarterly dividend of 21 cents per share, scheduled for payment on April 27, 2022. Shareholders on record as of April 5, 2022 will receive this dividend. The company generated revenue of $6.32 billion in fiscal 2021 and employs approximately 17,000 people. Future dividends will be determined by Agilent’s board of directors and may vary based on company performance.
Agilent Technologies Inc. (NYSE: A) showcased innovative laboratory automation solutions at the SLAS2022 International Conference in Boston, Massachusetts, from February 5 to 9, 2022. Their modular automation solutions enhance workflows in cell analysis, mass spectrometry, and genomics, leading to improved sample preparation, accuracy, and efficiency. Key highlights include the BioTek BioSpa Live Cell Analysis System and the compliant VWorks software for integrated laboratory automation. Agilent reported $6.32 billion in revenue for fiscal 2021, indicating strong market presence and innovation capacity.
Agilent Technologies (NYSE: A) has signed a Research Collaboration Agreement with the Singapore Institute of Food and Biotechnology Innovation (SIFBI) to advance food research over the next two years. This partnership supports Singapore's goal to produce 30% of its nutritional needs by 2030, enhancing food resilience and security. Agilent will provide analytical technology and support for developing efficient methods for food innovation. With over 800 local scientists and engineers, Agilent aims to boost Singapore's food innovation ecosystem, ultimately promoting healthier, sustainable food options.
Agilent Technologies Inc. (NYSE: A) has announced the launch of the Agilent Seahorse XF Pro Analyzer, designed to enhance cellular metabolism analysis in the pharma and biopharma sectors. The XF Pro offers improved performance and user accessibility, facilitating real-time monitoring of live cells. This new technology aims to help researchers identify drug targets and optimize disease models while ensuring better data precision in immunotherapy and preclinical safety assessments.